Halda Therapeutics Raises $126M in Series B Extension to Advance Two Cancer Candidates

Overview

The Connecticut-based biotech, which emerged from stealth last year, has secured $202 million to date as it looks to move two assets targeting prostate and breast cancer into the clinic.
Halda Therapeutics, a Connecticut-based biotech founded by Yale professor and entrepreneur Craig Crews, announced Monday that it has raised $126 million in a Series B extension to move two candidates into clinical trials for patients with prostate and breast cancer.

Novel cancer therapies

• The biotech has been developing a new class of cancer therapies known as Regulated Induced Proximity Targeting Chimeras (RIPTAC). 
• According to Halda, these assets use a “hold and kill” mechanism using two proteins, one cancer-specific and one with an essential function. 
• The candidates are designed to help retract essential cell function and cause the death of the cancer cells while preserving non-cancer tissue.

Words from the CSO: Halda

This financing will enable us to bring to patients our oral, selective and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Kat Kayser-Bricker, Halda chief scientific officer, said in a statement.

About the HLD-0915

• Halda’s lead asset, HLD-0915, aims to treat metastatic, castration-resistant prostate cancer (mCRPC) and will start Phase I trials in the first half of 2025, thanks to the latest round of funding.
• The cash from the Series B extension will also allow the biotech to support the development of a RIPTAC asset for metastatic breast cancer, which is in the preclinical stage. 
• Funding will also be used to build the team at Halda further and develop more products using the RIPTAC platform.

The Investors

• New investors participating in the funding, which brought the total amount raised to date to $202 million, included RA Capital Management, Deep Track Capital, Frazier Life Sciences, Vida Ventures, Boxer Capital and Taiho Ventures. 
• The Series B extension also included participation from existing investors such as Canaan Partners, Connecticut Innovations, Access Biotechnology and Elm Street Ventures.

From the Frazier Life Sciences

• Novel mechanisms are desperately needed to address resistance to standard of care therapies across several tumor types. RIPTAC therapies can selectively kill cancer cells based on differential protein expression in orally bioavailable medicines,” Joe Cabral, principal at Frazier Life Sciences, said in a statement. 
• This innovation has the potential to treat both advanced cancer patients with heterogeneous resistance adaptations, as well as patients with earlier stages of disease.

About Halda

• Halda emerged from stealth last year with $76 million in its arsenal. 
• Crews was also the founder of Arvinas, which has since worked with major pharmaceutical companies including Pfizer, which inked a potential $2 billion deal with Arvinas in 2021.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!